Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 23

Trial Status

Completed1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT05924997Phase 1/2Unknown
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
PrincipalinvestigatorStart date: 2023-07-01
NCT04962958Phase 2Completed
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
AntimetabolitesAntineoplastic AgentsCarcinoma+6 more
PrincipalinvestigatorStart date: 2021-12-27
NCT05913661Phase 2Unknown
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
CarcinomaDigestive System NeoplasmsFirst-line Treatment+2 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT05924997Phase 1/2PrincipalInvestigator

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Unknown
NCT04962958Phase 2PrincipalInvestigator

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

AntimetabolitesAntineoplastic AgentsCarcinoma+6 more
Completed
NCT05913661Phase 2PrincipalInvestigator

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

CarcinomaDigestive System NeoplasmsFirst-line Treatment+2 more
Unknown

All 3 trials loaded